NovaBay Pharmaceuticals Inc
$ 1.53
-1.29%
26 Feb - close price
- Market Cap 40,493,300 USD
- Current Price $ 1.53
- High / Low $ 1.69 / 1.42
- Stock P/E 0.06
- Book Value -2.23
- EPS 25.80
- Next Earning Report 2026-04-01
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.87 %
- ROE -5.16 %
- 52 Week High 99.75
- 52 Week Low 1.42
About
NovaBay Pharmaceuticals, Inc., a medical device company, develops products for the eye care markets in the United States and internationally. The company is headquartered in Emeryville, California.
Analyst Target Price
$0.85
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-12 | 2025-04-02 | 2024-12-31 | 2024-11-07 | 2024-08-13 | 2024-05-09 | 2024-03-26 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-30 |
| Reported EPS | -0.23 | -0.34 | -0.4 | -1.994 | -0.59 | -1.37 | -0.15 | -1.33 | -0.37 | -0.64 | -0.85 | -0.78 |
| Estimated EPS | -0.01 | -0.21 | -0.24 | -1.2 | -0.3 | -1.23 | -0.15 | -0.3 | -0.4 | -0.56 | -0.91 | -0.17 |
| Surprise | -0.22 | -0.13 | -0.16 | -0.794 | -0.29 | -0.14 | 0 | -1.03 | 0.03 | -0.08 | 0.06 | -0.61 |
| Surprise Percentage | -2200% | -61.9048% | -66.6667% | -66.1667% | -96.6667% | -11.3821% | 0% | -343.3333% | 7.5% | -14.2857% | 6.5934% | -358.8235% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-04-01 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| Sep 2025 | |
|---|---|
| Payment Date | 2025-09-29 |
| Amount | $0.8 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NBY
2026-02-26 00:51:52
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) stock recently traded below its 50-day moving average of $24.48, with shares closing at $1.65 after falling to $1.55. Despite this dip, institutional investors increased their stakes in Q4, with State Street Corp notably boosting its position by 970.5%. NovaBay, a clinical-stage biotech company focused on non-antibiotic anti-infectives, currently has a market capitalization of $42.77 million and a negative P/E ratio, reflecting its unprofitable status.
2026-02-25 10:52:50
This article focuses solely on the "Tangible book value per share" for NovaBay Pharmaceuticals, Inc. (GETTEX:B9P1). It appears to be a stub or a data point from a financial platform, showing no actual financial figures or detailed analysis. The content primarily consists of navigation, copyright information, and links to various features of the TradingView platform.
2026-02-22 02:44:54
NovaBay Pharmaceuticals Inc. has launched Avenova Eye Health Support, an over-the-counter oral supplement designed to comfort dry eyes and promote overall eye health. The supplement contains MaquiBright®, a maqui berry extract, and omega-3 oils. Clinical studies cited by the company showed significant improvement in tear production and dry eye discomfort for participants using the MaquiBright® extract.
2026-02-21 06:57:59
NovaBay Pharmaceuticals (NYSE:NBY) implemented a 1-for-5 reverse stock split on Thursday, effective 4:15 p.m. ET. Post-split, the stock closed at $0.51 and is currently trading at $0.60, reflecting a gain, though InvestingPro analysis suggests it is overvalued. The company also announced a $100 million at-the-market sales agreement and a $134 million private placement of pre-funded warrants to strengthen its financial position.
2026-02-21 01:10:45
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) implemented a 1-for-5 reverse stock split, effective Thursday, combining five shares into one. The stock closed at $0.51 before the split and now trades at $0.60, showing a 14.73% gain despite being considered overvalued with an 89% year-to-date decline. This move follows board approval and recent financial activities including an ATM sales agreement and a private placement of pre-funded warrants.
2026-02-20 22:18:33
NovaBay Pharmaceuticals (NBY) implemented a 1-for-5 reverse stock split on February 20, 2026, which became effective at 4:15 p.m. Eastern time. This action followed shareholder approval and board authorization, consolidating every five shares into one without altering par value or shareholder ownership percentages. The stock will trade on a split-adjusted basis on the NYSE American under the symbol "NBY" starting February 23, 2026, with a new CUSIP.
